In this study, we successfully knocked-in the BRCA1 E255* and the BRCA2 C711* mutations into the Capan-2 and T3M4 PDAC cell lines and in the MCF7 breast cancer cell-line, using CRISPR/Cas9-mediated technology. This evidence concerns the gene BRCA2 and breast cancer.